Key Points
- Director Gregg Williams purchased 1,737,765 shares of Vivani Medical (NASDAQ:VANI) on Jan. 15 at $1.14 per share for about $1.98M, raising his holdings to 26,564,109 shares (a 7% increase, ~ $30.28M value).
- The Jan. 15 trade is part of repeated, sizable insider buys by Williams in recent months, including 3,703,703 shares on Oct. 27 at $1.62 (~$6.0M) and similar purchases in Nov. and Dec., indicating ongoing insider accumulation.
- Company context: Vivani Medical has a market cap of roughly $99M, a negative EPS (loss) profile, mixed analyst ratings averaging "Hold" with a $4.00 target, and a one‑year stock range of $0.91–$1.92.
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,737,765 shares of the company's stock in a transaction that occurred on Thursday, January 15th. The shares were purchased at an average cost of $1.14 per share, for a total transaction of $1,981,052.10. Following the completion of the transaction, the director owned 26,564,109 shares in the company, valued at approximately $30,283,084.26. This represents a 7.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Gregg Williams also recently made the following trade(s):
- On Monday, December 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The stock was acquired at an average cost of $1.14 per share, with a total value of $1,981,052.10.
- On Saturday, November 15th, Gregg Williams bought 1,737,764 shares of Vivani Medical stock. The shares were acquired at an average price of $1.14 per share, with a total value of $1,981,050.96.
- On Monday, October 27th, Gregg Williams purchased 3,703,703 shares of Vivani Medical stock. The stock was acquired at an average price of $1.62 per share, for a total transaction of $5,999,998.86.
Vivani Medical Stock Performance
NASDAQ VANI opened at $1.36 on Wednesday. Vivani Medical, Inc. has a one year low of $0.91 and a one year high of $1.92. The company has a 50-day simple moving average of $1.35 and a 200-day simple moving average of $1.39. The firm has a market capitalization of $99.21 million, a PE ratio of -3.02 and a beta of 3.07.
Vivani Medical (NASDAQ:VANI - Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. Equities analysts forecast that Vivani Medical, Inc. will post -0.41 earnings per share for the current year.
Wall Street Analysts Forecast Growth
VANI has been the subject of several recent research reports. Zacks Research upgraded shares of Vivani Medical from a "strong sell" rating to a "hold" rating in a research report on Wednesday, November 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vivani Medical in a research report on Friday, January 9th. Finally, Wall Street Zen upgraded shares of Vivani Medical to a "sell" rating in a research report on Saturday, November 22nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Vivani Medical has an average rating of "Hold" and an average target price of $4.00.
Get Our Latest Report on VANI
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Susquehanna International Group LLP boosted its holdings in Vivani Medical by 100.5% during the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company's stock worth $46,000 after buying an additional 16,200 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Vivani Medical in the third quarter valued at $26,000. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Vivani Medical during the 2nd quarter valued at $25,000. Institutional investors and hedge funds own 6.78% of the company's stock.
About Vivani Medical
(
Get Free Report)
Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.
The company's flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
